NRG1 and familial pancreatic carcinoma: Data have been presented on zenocutuzumab, an inhibitor of human epidermal growth factor receptor 2 (HER2) and 3 (HER3), which has shown promising efficacy in patients with pancreatic cancer carrying the fusion in the neuregulin 1 (NRG1) gene.